Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck

Maria Secrier1,2, Lara McGrath3, Felicia Ng4

  • 1Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

PubMed

Insights

Identifying new biomarkers for head and neck squamous cell carcinoma (HNSCC) can improve immunotherapy response. This study characterized the tumor microenvironment (TME) and found that tertiary lymphoid structures (TLS) and T-cell receptor (TCR) richness predict patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Head and neck squamous cell carcinoma (HNSCC) is a complex disease with impaired immune surveillance.
  • Current immunotherapy patient selection relies on markers like PD-L1, but many patients still progress.
  • Improved strategies are needed to identify HNSCC patients who will benefit from immunotherapy.

Purpose of the Study:

  • To characterize the tumor microenvironment (TME) in HNSCC.
  • To identify novel biomarkers for predicting response to immune checkpoint blockade therapy.
  • To explore the relationship between genomic features, immune cell composition, and clinical outcomes in HNSCC.

Main Methods:

  • Gene expression and immunohistochemistry (IHC) profiling of 162 HNSCC primary tumors.
  • T-cell receptor (TCR) repertoire analysis and whole-exome sequencing.
  • Analysis of immune/stromal composition to define TME categories.

Main Results:

  • Five distinct HNSCC TME categories were identified: cytotoxic, plasma cell rich, dendritic cell rich, macrophage rich, and immune-excluded.
  • Cytotoxic and plasma cell rich subgroups showed phenotypes resembling tertiary lymphoid structures (TLS), linked to immunotherapy response.
  • Increased TCR repertoire richness was observed in these subgroups and in never-smokers.
  • APOBEC mutational patterns were enriched in the plasma cell high subgroup.
  • Specific signaling pathway patterns (Ras/ERK, PI3K/AKT) correlated with immune phenotypes.

Conclusions:

  • Beyond CD8/CD3 infiltration and PD-L1, additional biomarkers like TCR productive clonality, smoking history, and TLS index may improve HNSCC patient selection for immunotherapy.
  • Understanding the genomic and immune landscape of HNSCC is crucial for developing personalized treatment strategies.
  • The identified TME categories and biomarkers offer potential for refining immunotherapy efficacy in HNSCC.